European regulators have started an in-depth review of the benefits and risks of Ariad Pharmaceuticals Inc's leukaemia medicine Iclusig. The European Medicines Agency (EMA) said on Friday the probe would look particularly at the risk of blood clots or blockages in the arteries or veins associated with the medicine.
Help employers find you! Check out all the jobs and post your resume.
